To include your compound in the COVID-19 Resource Center, submit it here.

Pozen, Xcel MT 300 marketing deal

POZN granted Xcel (San Diego, Calif.) exclusive U.S. rights to market POZN's MT 300 injectable dihydroergotamine mesylate

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE